Anticancer Therapies – Products

Plasticell’s high throughput screen for stem cell differentiation joins list of the most significant technology products developed globally in the last 49 years.

DPX-Survivac will be tested in patients with ovarian cancer.

Company receives £1.16m award from the UK’s Technology Strategy Board.

The trial is designed to demonstrate the overall survival benefit of IMA901 in combination with standard first-line therapy in RCC patients.

Trial could generate future alternative treatment for metastatic melanoma.

PharmaNet collaborate with CITN to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.

Eleven abstracts on nimotuzumab to be presented at ASCO.

Integrated capabilities offer deeper, broader understanding of proteomes and biological pathways.

Researchers in the US used a form of Benitec’s ddRNAi as a key component of their therapeutic molecule in preclinical studies both in vitro and in vivo.

Marks RPC's 3rd medical conference participation this year.